^
Association details:
| Biomarker: | HR negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Libtayo (cemiplimab-rwlc) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Published date:
11/22/2022
Excerpt:
60 HER2- patients (28 HR+ and 32 HR-) received Cemi arm treatment….Anti-PD-1 therapy with Cemi resulted in a higher predicted pCR rate in HR-/HER2- 55 rate% disease compared to control at 29%....
